|
|
 |
|
|
|
| Clinical Trials |
To enroll please contact your physician or call us at (310) 285-7242 |
 |
|
| Current Clinical Trials |
 |
Clinical Trials for Cancer |
 |
|
 Breast |
|
|
 |
Breast |
|
|
A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer (CTKI258A 2202)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Breast |
|
|
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients with Metastatic Breast Cancer (A011-08)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Breast |
|
|
A Randomized, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (LPT112515 )
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
Breast |
|
|
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3
Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast
Cancer at High Risk of Recurrence (D-CARE) (20060359)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
Breast |
|
|
A randomized double-blind, placebo-controlled study of everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole (CRAD001Y2301)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Chronic Lymphocytic Leukemia (CLL) |
|
|
|
Chronic Lymphocytic Leukemia (CLL) |
|
|
Phase II Study of Forodesine in Subject with Chronic Lymphocytic Leukemia (CLL)(BCX1777-210)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Colorectal (CRC) |
|
|
|
Colorectal (CRC) |
|
|
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination with mFOLFOX6 to the Efficacy of Bevacizumab in Combination with mFOLFOX6 in Patients with Previously Untreated, KRAS Wild-Type, Unresectable mCRC (20070509)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Colorectal (CRC) |
|
|
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as a Second-line Treatment in Subject with Metastatic Colorectal Cancer w/ Kras (Amgen 20060141 SPIRITT)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Colorectal (CRC) |
|
|
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination with AMG 479 or AMG 655 versus FOLFIRI for the Second-line Treamtnet of KRAS-mutant Metastatic Colorectal Carcinoma (Amgen 20060579)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Heptocellular Carcinoma (HCC) |
|
|
|
Heptocellular Carcinoma (HCC) |
|
|
An Open-Label, Ranodmized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Heptocellular Carcinoma (HCC) (M10-963)
Phase
III
For more information call
(310) 285-7242 |
|
|
|
|
|
|
|
|
|
Lymphoma |
|
|
|
Lymphoma |
|
|
An Open-Label, Dose-Escalation Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma (C16002)
Phase
I
For more information call
(310)285-7242 |
|
|
|
|
Lymphoma |
|
|
An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With
Bendamustine in Combination With Ofatumumab in Previously Untreated Patients
With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL) (USOR #09227)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Mantle Cell Lymphoma |
|
|
|
Mantle Cell Lymphoma |
|
|
A Phase II, Multicenter, Single-Arm, Open-Label Study of Single-Agent Lenalidomide (Revlimid) in Patients with Mantle Cell non-Hodgkins Lymphoma who have relapsed after Bortezomib or are Refractory or Intolerant to Bortezmib (CC-5013-MCL-001)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Melanoma |
|
|
|
Melanoma |
|
|
An Open-Label Multicenter, Phase III Trial of ABI-007 vs. Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma (CA033)
Phase
III
For more information call
(310) 285-7242 |
|
|
|
|
|
|
|
|
|
Multisite/Multiorgan |
|
|
|
Multisite/Multiorgan |
|
|
Phase 1b/2 Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects with Relapsed Solid Tumors and Multiple Myeloma (PX-171-007)
Phase
IB/II
For more information call
(310)285-7242 |
|
|
|
|
Multisite/Multiorgan |
|
|
A Phase I Dose-Escalation Study of PHA-739358 Administered in Combination with Docetaxel or Gemcitabine or Bevacizumab in Adult Patients with Advanced Solid Tumors. (AURA-6202-008)
Phase
I
For more information call
(310)285-7242 |
|
|
|
|
Multisite/Multiorgan |
|
|
A Phase I, Multicenter, Open Label, Dose Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily x 5 followed by a 21 day rest period in Patients with Advanced Solid Tumors (PRLX93936-0001)
Phase
I
For more information call
(310)285-7242 |
|
|
|
|
Multisite/Multiorgan |
|
|
A Phase 1, First-in-Human Study evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects with Advanced Solid Tumors (AMG 208 20080895)
Phase
I
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Myeloma |
|
|
|
Myeloma |
|
|
An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma (PX-171-004)
Phase
II
For more information call
(310) 285-7242 |
|
|
|
|
Myeloma |
|
|
Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE® and Dexamethasone (VD) versus VELCADE®, Melphalan, and Prednisone (VMP) (UPFRONT C05009)
Phase
IIIB
For more information call
(310)285-7242 |
|
|
|
|
Myeloma |
|
|
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma (PX-171-009)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (CP12-0708)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
A Multinational, Randomized, Double-Blind, Study Comparing Afibercept vs Placebo in patients Treated with Second-Line Docetaxel after Failure of One Platinum Based therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EFC10261)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Single-Agent Tarceva Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA NSCLC Who Have EGFR-Positive Tumors (OSI 774-302)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of PF02341066 versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK)gene Locus (A8081007)
Phase
III
For more information call
(310) 285-7242 |
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
Phase 2, Open-Label Single Arm Study of the efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation of Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (A8081005)
Phase
II
For more information call
(310) 285-7242 |
|
|
|
|
Non-Small Cell Lung Cancer (NSCLC) |
|
|
A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer (E7389-G000-205)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Pancreatic |
|
|
|
Pancreatic |
|
|
A Phase 2 Double-Blind, Placebo Controlled, Multicenter Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; and Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen versus a Gemcitabine Regimen with Placebo, in Patients with Post-resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations. (GI-4000-02)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
Pancreatic |
|
|
A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine
versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma
of the Pancreas(CA046)
Phase
III
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Polycythemia/Myeloproliferative Disease |
|
|
|
Polycythemia/Myeloproliferative Disease |
|
|
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) (INCB 18242-351)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
|
Prostate |
|
|
|
Prostate |
|
|
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (CRPC2 AFFIRM MDV3100)
Phase
III
For more information call
(310) 285-7242 |
|
|
|
|
|
|
|
|
|
Renal Cell |
|
|
|
Renal Cell |
|
|
An Open-Label, Single-Arm, Phase II Trial of IV BI6727 in Patients with Locally Advanced, Medtastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy (1230.2)
Phase
II
For more information call
(310)285-7242 |
|
|
|
|
|
|
|
|
 |
|
 |
|
|
Treatments for Genetic Disorders |
|
|
Gaucher |
|
|
|
Gaucher |
|
|
Gaucher Program Grant
Phase
IV
For more information call
(310)285-7242 |
|
|
|
|
Gaucher |
|
|
A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme. (GZGD02607)
Phase
III
For more information call
(310) 285-7242 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
|
|
